Welcome to the first CEO blog of 2022, one I’m delighted not to have penned from an overpriced hotel room in San Francisco – my normal place of work this time of year. A new year normally means a fresh start, but it seems the year will again be dominated by how governments and global economies will respond to the COVID-19 pandemic.
I’m delighted to finally be able to leave the house today after my period of isolation after a positive COVID-19 test. It was such a shame not to be able to join our bioprocessing community last week for the 18th annual bioProcess UK conference but I have been enjoying looking at the photos from this great event. News over the weekend of the Omnicron variant has led to the postponement of the WTO Ministerial meeting in Geneva where waivers on the IP of COVID-19 vaccines were to be discussed, so I’m no longer expecting to see global policy set in Geneva this week.
Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell’s pipeline, including QEL-001 in liver transplantation and pipeline programs in neuroinflammation and autoimmunity.
John Brown will retire at the end of 2021 after nine years in the role.
Dr John Brown, CBE, FRSE, Chairman of Cell and Gene Therapy Catapult (CGT Catapult), will retire from the role at the end of 2021 after completing three successive terms. The Nomination Committee will establish a process, led by Hilary Newiss, to identify and appoint his successor in due course.
London, UK, 16th September 2021 – A 6-month collaborative project was announced today that will help to accelerate the introduction of regulated advanced gene therapies that use Adenovirus-associated vectors (AAVs).
Earlham Enterprises Ltd has appointed two Non-Executive Directors to help push forward its work translating the cutting-edge research expertise and infrastructure at the Earlham Institute into applications that deliver impact.
Have you reviewed your post-Brexit patent and SPC pharma strategies? In a 32-page special report pharma patent specialists Garreth Duncan and Jennifer O'Farrell shine a spotlight on the opportunities and challenges that the pharma industry faces.
Cancer Research UK and Capital Enterprise, together with Roche UK, have launched the Cancer Tech Accelerator programme to support innovative technologies that can advance the early detection, diagnosis, monitoring or treatment of cancer.
Scientists across Norwich Research Park institutes are part of a major integrated UK research-industry programme led by The Alan Turing Institute, seeking out the best talent in AI and data science, developing bioscience leaders and supporting the UK economy.